The Predictive Value of Longitudinal Monitoring of Mutated EGFR in Plasma of Advanced NSCLC Patients on First-Line EGFR-TKIs

被引：0

作者：

Szpechcinski, A. ^{[1
]}

Bryl, M. ^{[2
]}

Wojda, E. ^{[1
]}

Czyzewicz, G. ^{[3
]}

Swiniuch, D. ^{[4
]}

Szwiec, M. ^{[5
]}

Ramlau, R. ^{[4
]}

Sliwinski, P. ^{[1
]}

Barinow-Wojewodzki, A. ^{[2
]}

Chorostowska-Wynimko, J. ^{[1
]}

机构：

[1] Inst TB & Lung Dis, Warsaw, Poland

[2] EJ Zeyland Wielkopolska Ctr Pulmonol & Thorac Sur, Poznan, Poland

[3] John Paul II Specialist Hosp, Krakow, Poland

[4] Med Univ Poznan, Poznan, Poland

[5] Univ Hosp Zielona Gora, Zielona Gora, Poland

来源：

JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期

关键词：

non-small cell lung cancer; EGFR mutations; liquid biopsy;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

EP08.02-07

引用

页码：S434 / S435

页数：2

共 50 条

[31] Prognostic Value of Clinical, Immune and Biochemical Markers in EGFR-Mutant NSCLC Patients Treated with First-Line EGFR TKIs
Ng, I.
Kumarakulasinghe, N.
Syn, N.
Teng, R.
Soo, R.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2208 - S2209
[32] Local Ablative Therapy Improves Survival in Patients with Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated with First-Line EGFR-TKIs
Xu, Q.
Liu, H.
Xu, Y.
Zhou, C.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : S93 - S93
[33] Local Consolidative Radiation Prolongs Disease Control of Patients with Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated with First-Line EGFR-TKIs
An, N.
Wang, H.
Jing, W.
Zhu, H.
Yu, J.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E494 - E495
[34] The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
Huang, Yen-Hsiang
Hsu, Kuo-Hsuan
Chin, Chun-Shih
Tseng, Jeng-Sen
Yang, Tsung-Ying
Chen, Kun-Chieh
Su, Kang-Yi
Yu, Sung-Liang
Chen, Jeremy J. W.
Chang, Gee-Chen
CANCER RESEARCH AND TREATMENT, 2022, 54 (02): : 434 - 444
[35] Beyond disease-progression: Clinical outcomes after EGFR-TKIs in a cohort of EGFR mutated NSCLC patients
Tudor, Roxana Aline
D'Silva, Adrijana
Tremblay, Alain
MacEachern, Paul
Morris, Don
Brenner, Darren
Kopciuk, Karen
Bebb, Dafydd Gwyn
PLOS ONE, 2017, 12 (08):
[36] Bone metastasis reduces responsiveness to EGFR-TKIs in patients with EGFR-mutated advanced lung adenocarcinoma
Zheng, X.
Huang, C.
Lin, G.
ANNALS OF ONCOLOGY, 2018, 29
[37] Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs
Xu, Qinghua
Zhou, Fei
Liu, Hui
Jiang, Tao
Li, Xuefei
Xu, Yaping
Zhou, Caicun
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : 1383 - 1392
[38] Longitudinal Monitoring of EGFR Mutations in Plasma of EGFR Mutant NSCLC Patients Treated with EGFR TKIs: Korean Lung Cancer Consortium
Lee, Ji Yun
Bai Yali
Wei Xiumin
Hyeon, Bak So
Lee, Ho Yun
Sun, Jong-Mu
Lee, Se-Hoon
Ahn, Jin Seok
Cho, Eun Kyung
Kim, Hye Ryun
Min, Young Joo
Kim, Dong-Wan
Park, Keunchil
Qing, Xu
Mao, Mao
Ahn, Myung-Ju
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S358 - S358
[39] Efficacy of early stereotactic body radiotherapy to the primary lung lesion in patients with NSCLC harboring sensitive EGFR mutations treated with first-line EGFR-TKIs
Tao, D.
Lei, H.
Tan, J.
Yang, D.
Jiang, Y.
Zhou, W.
Wang, Y.
Wu, Y.
ANNALS OF ONCOLOGY, 2023, 34
[40] Therapeutic Effect Of First-Line EGFR-TKIs Combined With Concurrent Cranial Radiotherapy On NSCLC Patients With EGFR Activating Mutation And Brain Metastasis: A Retrospective Study
An, Ning
Wang, Haoyi
Li, Ji
Zhai, Xiaoyang
Jing, Wang
Jia, Wenxiao
Kong, Li
Zhu, Hui
Yu, Jinming
ONCOTARGETS AND THERAPY, 2019, 12 : 8311 - 8318

← 1 2 3 4 5 →